

Product datasheet for TL309805

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Relaxin 1 (RLN1) Human shRNA Plasmid Kit (Locus ID 6013)

Product data:

Product Type: shRNA Plasmids

Product Name: Relaxin 1 (RLN1) Human shRNA Plasmid Kit (Locus ID 6013)

Locus ID: 6013

Synonyms: bA12D24.3.1; bA12D24.3.2; H1; H1RLX; RLXH1

Vector: pGFP-C-shLenti (TR30023)

E. coli Selection: Chloramphenicol (34 ug/ml)

Mammalian Cell

Selection:

Puromycin

Format: Lentiviral plasmids

Components: RLN1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 6013).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: NM 006911, NM 006911.1, NM 006911.2, BC005956, BC005956.1, NM 006911.4

UniProt ID: P04808

Summary: Relaxins are known endocrine and autocrine/paracrine hormones, belonging to the insulin

gene superfamily. In humans there are three non-allelic relaxin genes, RLN1, RLN2 and RLN3, where RLN1 and RLN2 share high sequence homology. The protein encoded by this gene is synthesized as a single-chain polypeptide but the active form consists of an A chain and a B chain linked by disulfide bonds. Relaxin is produced by the ovary, and targets the mammalian reproductive system to ripen the cervix, elongate the pubic symphysis and inhibit uterine contraction. It may have additional roles in enhancing sperm motility, regulating blood pressure, controlling heart rate and releasing oxytocin and vasopressin. [provided by RefSeq,

Jan 2013]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).